Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.28 USD | +2.40% | -14.09% | -63.45% |
May. 14 | TRACON Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 14 | Transcript : TRACON Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.91M |
---|---|---|---|---|---|
Net income 2024 * | -20M | Net income 2025 * | -21M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.39
x | P/E ratio 2025 * |
-0.35
x | Employees | 17 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.8% |
Latest transcript on TRACON Pharmaceuticals, Inc.
1 day | +2.40% | ||
1 week | -14.09% | ||
1 month | -26.01% | ||
3 months | -64.64% | ||
6 months | -68.70% | ||
Current year | -63.45% |
Managers | Title | Age | Since |
---|---|---|---|
Charles Theuer
CEO | Chief Executive Officer | 60 | 06-06-30 |
Scott Brown
DFI | Director of Finance/CFO | 43 | 15-07-31 |
James L. Freddo
CTO | Chief Tech/Sci/R&D Officer | 69 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Mattingly
BRD | Director/Board Member | 66 | 14-12-25 |
Director/Board Member | 54 | 20-03-18 | |
Stephen Worland
BRD | Director/Board Member | 66 | 15-02-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.28 | +2.40% | 46,453 |
24-05-30 | 1.25 | -17.22% | 271,139 |
24-05-29 | 1.51 | +0.67% | 78,603 |
24-05-28 | 1.5 | +0.67% | 35,542 |
24-05-24 | 1.49 | -1.97% | 56,465 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.45% | 2.91M | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- TCON Stock